These are heady days for PharmaEssentia, a biotech that got its start 23 years ago in Taiwan, went public 10 years later and ...

In their high-profile competition in the diabetes and obesity markets, Eli Lilly has proven adept in playing catch up with ...

In its release on the CARDIO-TTRansform data, the ESC echoed AZ and Ionis’ point that Wainua suppressed circulating serum TTR ...

Mimrylo marks the second FDA new drug approval that Takeda has secured since CEO Julie Kim officially took the reins in June ...

On Monday, the U.S. Court of Appeals for the Third Circuit in Washington, D.C., ruled against Merck & Co., rejecting its ...

For decades, drugmakers have been confounded in the clinic by a rare form of hypertrophic cardiomyopathy. | Cytokinetics' ...

The FDA approval of Bixlenvo tees up a new HIV treatment option for virologically suppressed adults, including those on ...

By Alicia Cowley, MD, MBA, Medical Director, Phreesia Network Solutions | Endemic media and broad reach each do half the job.

McKesson Corporation is expanding its drug development and commercialization capacity to the tune of $2.25 billion. | The ...

Amgen and AstraZeneca’s inflammatory disease drug Tezspire has clinched a phase 3 win in eosinophilic esophagitis (EoE) as ...

RevMed’s leadership, too, highlighted the significance of Rasonque’s approval in a call with investors yesterday.

Though not without a bump along the way, Roivant-backed Priovant Therapeutics has pushed its dual TYK2/JAK1 inhibitor across ...